Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764396 · ClinicalTrials.gov registry record · NA
Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies
A NA study, sponsored by University of Michigan.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT04764396 is a NA study that was terminated before completion, run by University of Michigan. The registered enrollment target is 2 participants.
The verdict
NCT04764396, a NA study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a randomized study that will enroll patients scheduled for an endoscopic ultrasound biopsy of a pancreas lesion to be in the heparin or saline group during the procedure. The purpose of this study is to examine the effect of blood contamination, heparin priming of the fine needle biopsies, and pass number on tumor tissue quality in fine needle biopsies. The hypothesis for this study is that fine needle biopsy tissue quality of pancreatic masses decreases with increasing pass number due to blood contamination; this blood contamination can be ameliorated with priming of the needle with an anticoagulant such as heparin.
Interventions
- DRUG Saline
- COMBINATION_PRODUCT Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-03-12 |
| Est. Completion | 2021-07-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04764396
The ClinicalTrials.gov registry entry for NCT04764396 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04764396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04764396 about?
NCT04764396 is a clinical study titled "Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies". This is a randomized study that will enroll patients scheduled for an endoscopic ultrasound biopsy of a pancreas lesion to be in the heparin or saline group during the procedure. The purpose of this study is to examine the effect of blood contamination, heparin priming of the fine needle biopsies, ...
What is the current status of trial NCT04764396?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2021-03-12. Estimated completion is 2021-07-06.
What interventions are being tested in trial NCT04764396?
The interventions under investigation include: Saline (DRUG), Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04764396?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.